NMPA Denies Market Approval for Hengrui’s Plinabulin in Chemotherapy-Induced Neutropenia
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) announced in a stock exchange statement that the...
SciClone Pharmaceuticals’ Vaborem Approved for Phase III Clinical Trial in China
SciClone Pharmaceuticals Inc (HKG: 6600) has announced that a clinical trial filing for its Vaborem...
Janssen Withdraws Carvykti from UK Market Amid Manufacturing Concerns
US-based Janssen Pharmaceutical reportedly decided to withdraw Carvykti (ciltacabtagene autoleucel; cilta-cel) from the UK market...
BeiGene Declines Option for Leap Therapeutics’ DKN-01 Development Rights in Asia
US-based Leap Therapeutics Inc. (NASDAQ: LPTX) announced last week that China-based BeiGene Ltd. (HKG: 6160,...
Gracell Secures Non-Exclusive License for Cell Therapies from Seagen
China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) has secured a non-exclusive worldwide license to develop and...
Vas Healthcare Raises RMB 100 Million in Angel Financing for Robot Development
Vas Healthcare, a developer of vascular interventional surgery robots based in Beijing, has reportedly raised...
Hainan Poly Pharm’s Generic Gadovist Receives FDA Approval for MRI Use
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received marketing...
Jacobio Pharma’s JAB-24114 Receives CDE Approval for Phase I/IIa Clinical Study
China-based Jacobio Pharma (HKG: 1167) has announced that it has received approval from the Center...
Hengrui Pharmaceuticals’ Dexmedetomidine Nasal Spray Approved by NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing...
Asiflyer Bio Raises Millions in Pre-Series A Funding for Botox and ZFP Technology
Shanghai-based recombinant protein drug developer Asiflyer Bio has reportedly raised “tens of millions” of renminbi...
Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013
Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...
Shouyao Holdings Receives CDE Approval for Phase II Study of Third-Generation ALK Inhibitor
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...
Enlight Medical Technologies to Acquire Synexmed, Expand Vascular Intervention Capabilities
China-based Enlight Medical Technologies (Shanghai) Co., Ltd is set to fully acquire Japanese firm Japan...
Likang Life Sciences’ Personalized Neoantigen Vaccine LK101 Receives IND Approval
Likang Life Sciences has announced that it has received Investigational New Drug (IND) approval from...
AffaMed Technologies’ EDOF Intraocular Lenses Receive FDA Approval in Taiwan
AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced that it...
Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy...
AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...
Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development
Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel...
NMPA Accepts Market Filing for Guangdong Zhongsheng’s COVID-19 Drug RAY1216
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that the market filing for...
Mabwell Bioscience’s 9MW3811 Gains NMPA Approval for Clinical Trials in China
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...